TP53 and cancer: In most cancers tested in vitro, after 6–24 h of exposure to CAP, JNK phosphorylates p53 (Thr81), resulting in an impediment to its ubiquitylation by the murine double minute protein 2 (Mdm2), and, therefore, its subsequent degradation by the proteasome system.